EUVIMEDTutustu EUVIMEDiin
BeobachtungsstudieMixed-Methods-StudieOpen access · CC BY-NC 4.0

Quality of care in the course of subcutaneous versus intravenous trastuzumab administration in patients with breast cancer: an integrated time–motion study with mixed-methods research

Hsiang-Wen Lin iD, Chen-Yuan Lin, Tzu-Pei Yeh, Tien-Chao Lin, Wan-Chen Yeh, Lin-Chun Yang, Yu-Chieh Chen, Li-Ying Chiu, Chen-Teng Wu, Chih-Jung Chen, Yu-Fen Chen, Hwei-Chung Wang and 2 more

BMJ Open · 2023

DOI: 10.1136/bmjopen-2021-059288 ↗

At a glance

Beobachtungsstudie in BMJ Open, 2023. Written by Hsiang-Wen Lin and 13 co-authors. Institution: School of Pharmacy and Graduate Institute, College of Pharmacy, China Medical University, Taichung, Taiwan. Major MEDLINE topics: Breast Neoplasms, COVID-19. Cited 11 times so far (Crossref); 31 references. The full text is freely available (open access, CC BY-NC 4.0).

TiivistelmäSubjectsBibliografiset tiedotCiteRelated studies

Abstract (original language)

Objectives

This study aimed to compare the time required and concerns raised by various perspectives of participants regarding administering subcutaneous and intravenous trastuzumab for patients with breast cancer (BC).

Design

This observational time–motion study design with mixed-methods research (cross-sectional surveys and semistructured interviews) was conducted. The time spent on preparing or administering trastuzumab by different healthcare professionals (HCPs) was recorded. The data were analysed by descriptive/inferential statistical analyses, followed by thematic analyses.

Setting

Outpatient and inpatient administration units of a single medical centre in Taiwan.

Participants

The study included patients with early-stage BC who received subcutaneous or intravenous trastuzumab (n=93), and HCPs including two attending physicians, a nurse practitioner, two pharmacists and two nurses.

Result

Based on the perspectives of patients and HCPs, the subcutaneous form of trastuzumab was more efficient, less expensive and produced less discomfort in outpatient units than inpatient units. More participants preferred the subcutaneous form over the intravenous form in both outpatient and inpatient units. Pharmacists and nurse practitioners spent threefold more time on patients when preparing and administering the intravenous form in both outpatient and inpatient units. The concerns raised by patients and HCPs varied in certain aspects, including the injection skills, speed, mental distress (eg, needle phobia) and pain associated with the subcutaneous form. Almost all patients preferred receiving the subcutaneous form in outpatient units after the initial COVID-19 outbreak.

Conclusion

Patients with early-stage BC preferred receiving subcutaneous trastuzumab in outpatient units rather than inpatient units or the intravenous form before and after the COVID-19 outbreak. Such findings may serve as real-world evidence to facilitate better quality of care regarding administration of subcutaneous or intravenous trastuzumab in medical settings, and its feasible resolutions to balance the quality, concerns and efficiency of anticancer administration during the COVID-19 pandemic.

Subjects

MeSH terms (MEDLINE)

Breast NeoplasmsCOVID-19HumansFemaleTrastuzumabCross-Sectional StudiesPandemicsInjections, SubcutaneousAdministration, IntravenousErb-b2 Receptor Tyrosine Kinases

Author keywords

cancer painhealth & safetyquality in health care

Substances

TrastuzumabErb-b2 Receptor Tyrosine Kinases

Authors and institutions

  • School of Pharmacy and Graduate Institute, College of Pharmacy, China Medical University, Taichung, Taiwan.
  • Department of Pharmacy System, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
  • Department of Pharmacy, China Medical University Hospital, Taichung, Taiwan.
  • Division of Hematology and Oncology, China Medical University Hospital, Taichung, Taiwan.
  • School of Nursing, China Medical University, Taichung, Taiwan.
  • Department of Nursing, China Medical University Hospital, Taichung, Taiwan.

ORCID profiles: Hsiang-Wen Lin

Cite

APA

Lin, H. W., Lin, C. Y., Yeh, T. P., Lin, T. C., Yeh, W. C., Yang, L. C., Chen, Y. C., Chiu, L. Y., Wu, C. T., Chen, C. J., Chen, Y. F., Wang, H. C., Wu, Y. C., & Liu, L. C. (2023). Quality of care in the course of subcutaneous versus intravenous trastuzumab administration in patients with breast cancer: an integrated time–motion study with mixed-methods research. BMJ Open. https://doi.org/10.1136/bmjopen-2021-059288

Vancouver

Lin HW, Lin CY, Yeh TP, Lin TC, Yeh WC, Yang LC, et al. Quality of care in the course of subcutaneous versus intravenous trastuzumab administration in patients with breast cancer: an integrated time–motion study with mixed-methods research. BMJ Open. 2023. doi:10.1136/bmjopen-2021-059288

BibTeX
@article{Lin2023,
  author = {Lin, Hsiang-Wen and Lin, Chen-Yuan and Yeh, Tzu-Pei and Lin, Tien-Chao and Yeh, Wan-Chen and Yang, Lin-Chun and Chen, Yu-Chieh and Chiu, Li-Ying and Wu, Chen-Teng and Chen, Chih-Jung and Chen, Yu-Fen and Wang, Hwei-Chung and Wu, Yao-Chung and Liu, Liang-Chih},
  title = {Quality of care in the course of subcutaneous versus intravenous trastuzumab administration in patients with breast cancer: an integrated time–motion study with mixed-methods research},
  journal = {BMJ Open},
  year = {2023},
  doi = {10.1136/bmjopen-2021-059288}
}
Start for free →